RiverPark Advisors LLC Has $2.62 Million Stock Holdings in Eli Lilly and Company (NYSE:LLY)

RiverPark Advisors LLC lifted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 12.4% in the 4th quarter, Holdings Channel reports. The institutional investor owned 3,391 shares of the company’s stock after purchasing an additional 375 shares during the quarter. Eli Lilly and Company accounts for about 1.9% of RiverPark Advisors LLC’s portfolio, making the stock its 17th largest position. RiverPark Advisors LLC’s holdings in Eli Lilly and Company were worth $2,618,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Principal Financial Group Inc. grew its holdings in shares of Eli Lilly and Company by 5.3% in the third quarter. Principal Financial Group Inc. now owns 1,208,545 shares of the company’s stock valued at $1,070,698,000 after acquiring an additional 60,306 shares in the last quarter. Invst LLC boosted its position in shares of Eli Lilly and Company by 3.5% in the third quarter. Invst LLC now owns 5,552 shares of the company’s stock valued at $4,918,000 after acquiring an additional 189 shares during the period. McIlrath & Eck LLC grew its position in shares of Eli Lilly and Company by 3.4% during the 3rd quarter. McIlrath & Eck LLC now owns 481 shares of the company’s stock valued at $426,000 after purchasing an additional 16 shares in the last quarter. Virtu Financial LLC increased its stake in Eli Lilly and Company by 111.7% in the 3rd quarter. Virtu Financial LLC now owns 6,531 shares of the company’s stock worth $5,786,000 after acquiring an additional 3,446 shares during the last quarter. Finally, SOA Wealth Advisors LLC. lifted its position in Eli Lilly and Company by 2.4% during the third quarter. SOA Wealth Advisors LLC. now owns 864 shares of the company’s stock valued at $766,000 after purchasing an additional 20 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Insider Activity

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the firm’s stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the sale, the chief accounting officer now directly owns 5,840 shares in the company, valued at $4,778,521.60. This trade represents a 14.62 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.13% of the company’s stock.

Wall Street Analyst Weigh In

LLY has been the subject of a number of recent research reports. Leerink Partners set a $950.00 target price on Eli Lilly and Company in a research report on Friday, January 17th. Berenberg Bank set a $970.00 price objective on Eli Lilly and Company in a report on Thursday, January 16th. Citigroup lowered their target price on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a research note on Tuesday, January 28th. StockNews.com upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Friday, February 7th. Finally, Truist Financial raised their price target on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a “buy” rating in a report on Monday, February 3rd. Two research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $1,017.00.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $830.57 on Thursday. The company’s 50-day moving average price is $826.81 and its 200-day moving average price is $819.07. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00. The company has a market cap of $787.52 billion, a PE ratio of 70.93, a price-to-earnings-growth ratio of 1.40 and a beta of 0.51. Eli Lilly and Company has a twelve month low of $677.09 and a twelve month high of $972.53.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. On average, equities research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.